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Organ transplantation is one of the most important 
medical developments to have taken place in recent de-
cades. The number of individuals who benefit from this 
therapeutic resource every year continues to rise. 
For a number of years now, in addition to organ trans-
plants, multi-tissue transplants have also been possible. 
In these procedures, a number of tissues are harvested 
from a donor cadaver and used to reconstruct parts of 
the recipient’s body. Although multi-tissue transplants 
are not life-saving procedures, they can allow huge im-
provements in the recipient’s quality of life. 
The first multi-tissue transplant was performed on 23 
September 1998 when, at the Édouard-Herriot Hos-
pital in Lyon, a team led by Jean-Michel Dubernard 
transplanted the right hand (harvested from a deceased 
forty-one-year-old man) on to forty-eight-year-old New 
Zealander Clint Hallam, who had undergone an ampu-
tation.
Dozens of hand, upper limb and even lower limb 
transplants have been performed since. 
Of the various types of multi-tissue transplants, facial 
transplants are particularly complex from a technical 
standpoint and, above all, raise important ethical ques-
tions [1].
Those who are eligible for face transplants are care-
fully-selected individuals who have severe facial disfigu-
rations for various reasons and for whom there are no 
longer any alternative conventional plastic surgery or 
reconstruction options [2]. These individuals have se-
vere limitations when expressing themselves, in their 
interpersonal relationships and when breathing and eat-
ing. So far, a few dozen face transplants have been con-
ducted around the world. In most cases, the transplant 
regards a limited part of the face below the eyes, includ-
ing the cheeks down to the chin. All those cases ap-
proved for facial transplantation had extremely serious 
lesions, for which there were no reconstruction options. 
The first face transplant was performed in France at 
Amiens university hospital on 27 November 2005 by 
two teams (led by surgeons Jean-Michel Dubernard 
and Bernard Devauchelle). The patient (Isabelle Di-
noire, a 38-year-old mother-of-two whose face had been 
mauled by her Labrador) was transplanted the tip of a 
nose, lips and chin [3, 4].
The second face transplant was performed on 14 April 
2006 at Xijing military hospital in the city of Xian, in 
northern China, on a thirty-year-old patient, Li Guox-
ing, who had been attacked by a bear in 2004 [5]. This 
case was more complex than the previous transplant 
performed in France: two-thirds of the patient’s face 
were completely disfigured and the transplant involved 
a cheek, upper lip, nose and one eyebrow. The patient 
was discharged on 30 July 2006.
Although the techniques used have improved over 
time, facial transplantation is still a highly complex pro-
cedure. Suffice to think that for the first facial trans-
plant performed in Canada (in spring 2018 by surgeon 
Daniel Borsuk on a patient who had lost his nose and 
upper jaw in a hunting accident), it took 12 hours to 
harvest the tissues from the donor, 16 hours to prepare 
the recipient and 18 hours for the transplant. 
From a clinical standpoint, the issues connected with 
a highly complex procedure are obvious: “Facial al-
lografts could fail in the short or the long term. Techni-
cal failure, immunological problems, and poor selection 
of patients are significant risks” [6].
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Abstract
Facial transplantation is a complex technique that involves a number of risks. However, 
although it is not a lifesaving transplant, for individuals in dramatic conditions due to 
severe facial disfigurements, it constitutes the only possibility of recovering an accept-
able quality of life. For this reason, even from an ethical point of view, it is considered 
an important therapeutic resource, provided it is conducted in rigorously-controlled 
conditions. 
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Given the limited number of transplants performed 
to date, few follow-up data are available. Some of the 
data available highlight the numerous risks. For exam-
ple, a group of French researchers followed the results 
of seven patients who received transplants between 
2000 and 2009. Four of them had suffered firearm inju-
ries to the face, one had suffered burns and two had had 
facial tumours. Over an average of six years’ follow-up, 
two patients died (one due to failure of the transplant 
and infections and another committed suicide just over 
three years after the transplant). All the patients expe-
rienced episodes of rejection and the surviving patients 
continued taking high doses of steroids for years after 
the surgical procedure [7].
Face transplants also raise serious ethical issues, es-
pecially as regards self-identification, interpersonal rela-
tionships and social involvement [8, 9].
Further important issues regard the donor, the con-
sent expressed while he/she was alive and the family’s 
assent. 
The recipient’s mental health makes a crucial contri-
bution to the success or failure of a face transplant. For 
this reason, subjects have to be chosen very carefully. 
Indeed, the multidisciplinary transplant teams involved 
always include psychologists and social workers. 
When face transplants were in their early days, a 
number of authoritative institutions had expressed their 
opinion against face transplants. 
For example, in Great Britain, face transplantation 
was first proposed on 25 November 2002 by surgeon 
Peter Butler, of the Royal Free Hospital in London, for 
a twenty-three year-old woman, called Elizabeth, who 
had a very serious road traffic accident on 21 Septem-
ber 2001. An opinion was sought of the Royal College 
of Surgeons, which published its opinion in November 
2003 (the opinion was subsequently updated in Novem-
ber 2006) [10]. The report identified a number of issues 
that were particularly serious from a technical and scien-
tific, psychological and ethical point of view. The Royal 
College came to the following conclusions: “The working 
party believes that until there is further research and the 
prospect of better control of these complications it would 
be unwise to proceed with human facial transplantation. 
Equally this conclusion does not underestimate the suf-
fering of those patients who might be tempted by the 
prospect of facial transplantation. This conclusion is not 
adverse to facial transplantation. Indeed, it acknowledg-
es the need to recognise it as a possible future treatment. 
It simply means that the work should take a much more 
incremental approach than some of the current hype 
surrounding it has suggested” [11].
On 19 February 2002, the French Comité Consul-
tatif National d’Éthique (CCNE) was consulted re-
garding the topic by Laurent Lantieri, a plastic surgeon 
employed at the Henri Monor Hospital in Crétil, who 
proposed a protocol for facial transplantation. On 6 
February 2004, the CCNE published its opinion, which 
highlighted the related issues [12] and whose conclu-
sions were largely negative: “(T)here are ambiguities for 
both donors and recipients. Facial transplantations are 
not the same as organ transplantation and are far in-
deed from the graft of limbs. That is why they should 
not be practised before further and complimentary re-
search have made it possible to evaluate with precision 
the risks inherent to this type of intervention, and to 
validate the results” [13].
Although the practice should still be considered ex-
perimental, over a decade after these positions were 
adopted, the results obtained are encouraging. For ex-
ample, according to the data published in the Ameri-
can Journal of Transplantation in January 2015, olfac-
tory and eating abilities were restored in 100% of cases, 
whereas the ability to breathe, talk, and control facial 
expressions improved in 93%, 71% and 76% of cases, 
respectively [14]. 
The utmost caution is required. However, the encour-
aging results and the fact that the transplant is the only 
possible way to recover certain functions and to restore 
the possibility of social relationships for individuals with 
severe facial disfigurements, lead us to consider facial 
transplantation an important therapeutic resource and 
one for which there are no alternative options. 
The technique is also becoming a reality in Italy. In-
deed, on 21 May 2015, the National Transplant Cen-
tre (Centro Nazionale Trapianti) submitted its project 
“Partial or complete facial allograft for the treatment of 
complex disfigurements secondary to burns, traumas, 
malformations and tumours” to the Ethics Committee 
of the Italian National Institute of Health (Istituto Su-
periore di Sanità) for assessment. Italian regulations (at 
the time an agreement dated 14 February 2002 [15], 
which was subsequently renewed in 2018 [16]), indeed, 
require that for experimental transplants the National 
Transplant Centre must acquire the opinion of the Eth-
ics Committee and consult the Italian National Health 
Council (Consiglio Superiore di Sanità). The Italian Na-
tional Institute of Health Ethics Committee approved 
the protocol on 4 August 2015. Despite being aware 
that the technique is still in the experimental stage, that 
there are considerable risks and that it is not a lifesaving 
transplant, the Committee attached special importance 
to the fact that this kind of transplant may constitute 
the only possibility for restoring an acceptable quality of 
life for those in dramatic conditions [17]. Subsequently, 
on 10 November 2015, the Italian National Health 
Council also expressed its favourable opinion, express-
ing a need for “the inclusion, in the consent form, of the 
possibility of performing subsequent fine-tuning proce-
dures, in order to obtain the best possible result” [18]. 
This new transplantation frontier constitutes, for a 
very limited number of people with very severe disfig-
urements, the only possibility of improving their quality 
of life. The selection of candidates for transplantation, 
as well as the donors, must be particularly stringent. 
The use of this technique must therefore remain a rare 
event. 
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